Blue Earth Diagnostics Highlights Presentations on Fluciclovine F 18 at Upcoming 2021 ASCO Genitourinary Cancers Symposium

San Francisco, CA ( -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin® (fluciclovine F 18) at the upcoming ASCO 2021 Genitourinary Cancers Symposium (ASCO GU), from February 11 to 13, 2021, to be held in a virtual format. Details of selected oral poster presentations are listed below.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin is a registered trademark of Blue Earth Diagnostics, Ltd., or its related companies. All other marks are the property of their respective owners.

Highlighted Axumin (Fluciclovine F 18) Scientific Presentations

All ASCO GU presentations are available beginning Thursday, February 11, 2021, at 8 a.m. ET.

Track: Prostate Cancer – Advanced
Title: Diagnostic utility of (18)f-fluciclovine positron emission tomography (FACBC) in biochemically recurrent (BCR) prostate cancer (PCa) based on prior primary treatment modality for localized disease and the impact of FACBC findings on treatment selection.
Author(s): Marina N. Sharifi, Petra Lovrec, Jens C. Eickhoff, Aria Kenarsary, David F. Jarrard, John Floberg, Steve Y. Cho, Christos Kyriakopoulos, Hamid Emamekhoo
Session: Poster session
Abstract: 34

Track: Prostate Cancer – Advanced
Title: Use of 18F-fluciclovine PET/CT (FluPET) for prostate cancer (PC): Initial results from a prospective registry at a tertiary academic center.
Author(s): Risa L. Wong, Heather H. Cheng, Sarah K. Holt, Nathan Conrad, Hannah Loesch, Sara Fernandez, Rameen Sahoo, Zoya Bauer, Andrea Toulouse, Petros Grivas, Todd Yezefski, Kenneth J. Russell, Jonathan L. Wright, Michael T. Schweizer, Robert B. Montgomery, Jean H. Lee, Delphine L. Chen, Jing Zeng, Daniel W. Lin, Evan Y. Yu
Session: Poster session
Abstract: 29

Track: Trials in Progress – Advanced Prostate Cancer
Title: 18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.
Author(s): Pedro C. Barata, Charlotte Manogue, Ellen Jaeger, Malcolm Light, Patrick Cotogno, Elisa M. Ledet, Janeiro Goffin, Jodi L. Layton, Brian E. Lewis, A. O. Sartor
Session: Poster session
Abstract: TPS171

Blue Earth Diagnostics invites participants at the ASCO 2021 Genitourinary Cancers Symposium (ASCO GU) to attend the presentations above and to visit Blue Earth Diagnostics’ commercial exhibit in the Virtual Exhibit Hall.

Source: WIRE, B., 2021. Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming 2021 ASCO Genitourinary Cancers Symposium (ASCO GU). [online]